AbbVie Inc.

🇺🇸New York Stock Exchange
Back to all articles
AbbVie Inc. stock analysis ABBV overview
Neutral 0

AbbVie Canada: AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

📅 AbbVie Canada announced RIME Therapeutics as the recipient of the AbbVie Biotech Innovators Award in Quebec on April 30, 2026.

🤝 The award is a collaboration between AbbVie and adMare BioInnovations to foster innovation within Quebec's life sciences sector.

🏆 RIME Therapeutics was recognized for its function-first disruptive approach merging target discovery with simultaneous hit identification.

💻 The award provides RIME with one year of laboratory and office space at the adMare Innovation Centre in Montreal.

⚙️ Recipients gain access to shared equipment, services, and mentorship from AbbVie's scientific and business leaders.

🧬 RIME focuses on developing a peptide-based drug discovery platform targeting inflammation and immunology research.

🎯 The initiative supports early-stage biotech companies with potential in immunology, oncology, neuroscience, and aesthetics.

💬 Michael Mee, CEO of RIME Therapeutics, stated the award supports their path from novel biology to tractable chemistry.

🗣️ Matthew Carlyle, President and CEO of adMare BioInnovations, highlighted the focus on creating globally competitive Canadian life sciences companies.

🇨🇦 Stéphanie Sauvageau, Head of Medical at AbbVie Canada, emphasized commitment to fostering a thriving life sciences ecosystem in Quebec.

🔬 RIME Therapeutics was founded in 2025 as a Montreal-based start-up focused on protein-protein interaction targets.

⚠️ The program aims to accelerate scientific innovation and address pressing health challenges facing Canadians.

💼 adMare BioInnovations has helped create 39 companies with a combined value of $5.8 billion through its life sciences engine model.

🏢 AbbVie's therapeutic areas include immunology, oncology, neuroscience, eye care, and Allergan Aesthetics products.

Bullish Signals
  • AbbVie has recognized RIME Therapeutics as the recipient of the AbbVie Biotech Innovators Award, highlighting its commitment to fostering innovation in Quebec's life sciences sector.
  • RIME Therapeutics will receive a full year of laboratory and office space at the adMare Innovation Centre in Montreal, along with access to shared equipment and services to accelerate research.
  • The award includes mentorship from AbbVie's scientific and business leaders to help advance RIME's peptide-based drug discovery platform for inflammation and immunology diseases.
  • adMare BioInnovations has created 39 companies that have attracted $2.5 billion in risk capital, achieved a combined value of $5.8 billion, and created approximately 1,000 jobs through its life sciences model.
  • The AbbVie Biotech Innovators Award supports early-stage biotechnology companies focused on AbbVie's key therapeutic areas including immunology, oncology, neuroscience, and aesthetics.
  • RIME Therapeutics aims to address novel T cell biology with broad therapeutic applicability, merging target discovery with simultaneous hit identification for differentiated pipeline of medicines.
  • Matthew Carlyle, President and CEO of adMare BioInnovations, noted the partnership provides access to world-class infrastructure, expertise and mentorship to help Canadian biotech companies build value and scale.
Full Analysis
On April 30, 2026, AbbVie Canada announced in collaboration with adMare BioInnovations that RIME Therapeutics has been named the recipient of the AbbVie Biotech Innovators Award in Quebec. This national competition is designed to foster innovation and support growth within Quebec's life sciences sector, specifically targeting early-stage biotechnology companies with potential for transformational therapies in areas aligned with AbbVie's focus, including immunology, oncology, neuroscience, and aesthetics. Founded in 2025, RIME Therapeutics is a Montreal-based start-up developing a peptide-based drug discovery platform focused on identifying protein-protein interaction targets to accelerate therapy development for inflammation and immunology. The selection committee highlighted the company's function-first disruptive approach, which merges target discovery with simultaneous hit identification to address novel T cell biology. As part of the award package, RIME Therapeutics will receive one year of laboratory and office space at the adMare Innovation Centre in Montreal, along with access to shared equipment and services. Additionally, the recipient company will gain mentorship from AbbVie's scientific and business leaders to help advance research efforts. Michael Mee, CEO at RIME Therapeutics and Managing Director of Pre-Amp, noted that the award supports their Disruptide Platform, which aims to bridge the gap between knowing what to drug and knowing how to drug it, thereby accelerating the path from novel biology to tractable chemistry. Matthew Carlyle, President and CEO of adMare BioInnovations, emphasized that this partnership reflects a focus on helping create and scale globally competitive Canadian life sciences companies by providing world-class infrastructure and expertise. Stéphanie Sauvageau, Head of Medical at AbbVie Canada, stated that the award underscores AbbVie's commitment to fostering a thriving life sciences ecosystem in Quebec and across Canada, aiming to accelerate scientific innovation for pressing health challenges facing Canadians. adMare BioInnovations described its role as Canada's life sciences company creation engine, having helped create 39 companies that have attracted $2.5 billion in risk capital and achieved a combined value of $5.8 billion while creating approximately 1,000 jobs. The collaboration highlights AbbVie's broader mission to deliver innovative medicines that solve serious health issues in immunology, oncology, neuroscience, and eye care through its Allergan Aesthetics portfolio.